Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes

被引:42
作者
Brisson, M [1 ]
Edmunds, WJ
Gay, NJ
Law, B
De Serres, G
机构
[1] Publ Hlth Lab Serv, CDSC, London NW9 5EQ, England
[2] Univ Laval, Fac Med, CHUL Res Ctr, Publ Hlth Res Unit, Laval, PQ, Canada
[3] City Univ London, London EC1V 0HB, England
[4] Univ Manitoba, Winnipeg, MB, Canada
关键词
varicella zoster virus; vaccine; efficacy;
D O I
10.1016/S0264-410X(00)00100-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The objective of this study was to quantify key parameters describing varicella tester virus (VZV) vaccine efficacy. To do so a mathematical model was developed to represent breakthrough cases as a function of time after Vaccination in vaccine efficacy trials. Efficacy parameter sets were identified by fitting the predicted annual number of breakthrough infections with that observed in three clinical trials chosen to represent the plausible range of vaccine efficacy. Results suggest that varicella vaccination seems to result in a high proportion of individuals who are initially totally protected (97% for the base-case). However, individuals lose full protection relatively rapidly (3% per year for the base-case). Once total protection has waned individuals have a high probability of developing a breakthrough infection if exposed to varicella (73% of the probability in unvaccinated susceptibles for the base-case). Results also highlight that vaccine efficacy parameters should be estimated concurrently to take into account dependencies between parameters. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2775 / 2778
页数:4
相关论文
共 15 条
[1]  
ARBETER AM, 1986, PEDIATRICS, V78, P748
[2]   LIVE ATTENUATED VARICELLA VACCINE - IMMUNIZATION OF HEALTHY-CHILDREN WITH THE OKA STRAIN [J].
ARBETER, AM ;
STARR, SE ;
WEIBEL, RE ;
PLOTKIN, SA .
JOURNAL OF PEDIATRICS, 1982, 100 (06) :886-893
[3]   VARICELLA VACCINE TRIALS IN HEALTHY-CHILDREN - A SUMMARY OF COMPARATIVE AND FOLLOW-UP STUDIES [J].
ARBETER, AM ;
STARR, SE ;
PREBLUD, SR ;
IHARA, T ;
PACIOREK, PM ;
MILLER, DS ;
ZELSON, CM ;
PROCTOR, EA ;
PLOTKIN, SA .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1984, 138 (05) :434-438
[4]   OVER 5-YEAR FOLLOW-UP OF OKA/MERCK VARICELLA VACCINE RECIPIENTS IN 465 INFANTS AND ADOLESCENTS [J].
CLEMENTS, DA ;
ARMSTRONG, CB ;
URSANO, AM ;
MOGGIO, MM ;
WALTER, EB ;
WILFERT, CM .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (10) :874-879
[5]   The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France [J].
Coudeville, L ;
Paree, F ;
Lebrun, T ;
Sailly, JC .
VACCINE, 1999, 17 (02) :142-151
[6]   THEORETICAL EPIDEMIOLOGIC AND MORBIDITY EFFECTS OF ROUTINE VARICELLA IMMUNIZATION OF PRESCHOOL-CHILDREN IN THE UNITED-STATES [J].
HALLORAN, ME ;
COCHI, SL ;
LIEU, TA ;
WHARTON, M ;
FEHRS, L .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 140 (02) :81-104
[7]  
Halloran ME, 1997, AM J EPIDEMIOL, V146, P789
[8]  
JOHNSON C, 1989, PEDIATRICS, V84, P418
[9]   A long-term prospective study of varicella vaccine in healthy children [J].
Johnson, CE ;
Stancin, T ;
Fattlar, D ;
Rome, LP ;
Kumar, ML .
PEDIATRICS, 1997, 100 (05) :761-766
[10]   EFFICACY, IMMUNOGENICITY, SAFETY, AND USE OF LIVE ATTENUATED CHICKENPOX VACCINE [J].
KRAUSE, PR ;
KLINMAN, DM .
JOURNAL OF PEDIATRICS, 1995, 127 (04) :518-525